UMIT Private University for Health Sciences Medical Informatics and Technology: Results of a Collaborative Study at Campus Tyrol Argue in Favor of a Personalized Prostate Cancer Screening Approach

Food and Healthcare Press Releases Tuesday July 4, 2017 09:00
HALL, Austria--4 Jul--PRNewswire/InfoQuest

A simulation study published in BMC Public Health by researchers of the Tyrolean Health and Life Sciences University UMIT, the Oncotyrol center, the Medical University of Innsbruck and the University of Toronto highlights optimized use of prostate cancer screening.

(Photo: http://mma.prnewswire.com/media/529873/UMIT_Dr_Uwe_Siebert.jpg )
(Photo: http://mma.prnewswire.com/media/529874/UMIT_Nikolai_Muhlberger.jpg )

"Like most medical procedures also screening harbors benefits and risks. This gains increasing attention by the public," explains Prof. Dr. Uwe Siebert, Chair of the Department of Public Health, Health Services Research and Health Technology Assessment at UMIT and President-Elect of the Society for Medical Decision Making. "A major risk of prostate cancer screening is that of overdiagnosis and overtreatment. This refers to the diagnosis and treatment of clinically irrelevant tumors, which would not cause any complaints during men's lifetime and remain undetected without screening. Currently, there is no reliable method to distinguish clinically relevant from clinically irrelevant tumors. In consequence, also clinically irrelevant tumors may be treated, which unnecessarily exposes the affected patients to the unfortunately not uncommon long-term treatment complications such as erectile dysfunction, incontinence, bowel dysfunction."

The simulation model developed by the researchers within a ONCOTYROL research project for personalized medicine simulates the positive and negative effects of screening on the duration and quality of life of screening participants and analyses under which circumstances the potential harms of screening outweigh the potential benefits. Project Coordinator Ass. Prof. Dr. Nikolai Muhlberger summarizes the study findings as follows: "The study results suggest that participation in screening reduces the risk to die from prostate cancer and prolongs the life expectancy of participating men. However, when quality-of-life effects are considered as well, it is shown that primarily men with elevated familial prostate cancer risk benefit from screening, while in men with average prostate cancer risk overall the harms of screening prevail. In addition, the simulation predicts that the benefit of screening in men with elevated familial risk also strongly depends on their individual valuation of treatment-related long-term side-effects."

The urological experts in the research team, Prof. Dr. Wolfgang Horninger und Prof. Dr. Helmut Klocker, see the study as an important contribution towards a targeted application of prostate cancer screening. Horninger, the Dean of the Department of Urology at the Medical University of Innsbruck explains: "The study highlights the problem of overdiagnosis and illustrates the dependency of screening benefits on individual risk factors and preferences. Thus, it contributes to the improvement of patient counseling and supports an individual use of screening examinations, which all of us consider as important issues."

Contact: Prof. Dr. Uwe Siebert,   public-health@umit.at , +4350-8648-673930
Source: UMIT - The Health & Life Sciences University

Latest Press Release

Covaris Introduces the 96 oneTUBE-10 AFA Plate for Improved NGS Workflows

Today, Covaris Inc. announced the release of the 96 oneTUBE-10 AFA Plate, which enables scalable and simplified workflows by leveraging Covaris' gold standard focused-acoustic technology to meet rapidly increasing Next-Generation Sequencing (NGS) demands...

2018 Empire State Building Run-Up Lottery Registration Opens on November 14, 2017

Runners must enter by December 10 for a chance to participate in the 41st Annual Run-Up on Wednesday, February 7, 2018, at 8:00 p.m. Empire State Realty Trust, Inc. (NYSE: ESRT) today announced that lottery registration for the 2018 Empire State...

Alpinion Medical Systems Launches E-CUBE 8, the New Ultrasound Diagnostic System

One of South Korea's global medical device manufacturers, Alpinion Medical Systems introduced its new E-CUBE 8, the latest and last addition to the E-CUBE lineup. The E-CUBE 8 is a smart, reliable product that ensures high performance with outstanding...

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Blueprint for Change address Diabetes challenge , aligned with national NCD targets

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk...

Stryker announces publication of the DAWN(TM) Trial results in the New England Journal of Medicine

The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from...

Related Topics